Latest Breaking News On - Aprea therapeutics inc - Page 14 : comparemela.com

Form 3 Aprea Therapeutics, Inc For: May 16 Filed by: Gilad Oren

Form 3 Aprea Therapeutics, Inc For: May 16 Filed by: Gilad Oren
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGregorya korbelOren giladScottm coianteExchange commissionSecurities exchangeAprea therapeutics incSecurities exchange act

Aprea Therapeutics (NASDAQ:APRE) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Aprea Therapeutics (NASDAQ:APRE – Get Rating) from a buy rating to a hold rating in a research note released on Tuesday morning, Zacks.com reports. According to Zacks, “Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor […]

United statesSecurities exchange commissionZacks investment researchAprea therapeutics incSquarepoint opsVerition fund managementAprea therapeutics company profile get ratingMillennium managementRoyal bankAprea therapeuticsGet ratingExchange commissionFund managementTechnologies capital managementTherapeutics company profileNasdaq apre

Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc and Reports First Quarter 2022 Financial Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesMike grissingerGregorya korbelChristian schadeMarc dueyScott coianteWedbush pacgrowRichard petersOren giladZeev weissGreg korbelBernd seizingerJack hennemanScottm coianteExchange commissionAtrin pharmaceuticals inc

Aprea Therapeutics, Inc (NASDAQ:APRE) Receives $3 25 Average Target Price from Analysts

Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) have earned an average rating of “Hold” from the six analysts that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12 month price objective […]

Thomson reuterSecurities exchange commissionZacks investment researchMagnus financial groupAprea therapeutics incSquarepoint opsVerition fund managementMillennium managementRoyal bankAprea therapeuticsGet ratingMarketbeat ratingsInvestment researchExchange commissionFund managementNasdaq apre

Aprea Therapeutics, Inc (NASDAQ:APRE) Given Average Rating of Hold by Brokerages

Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) have been given a consensus rating of “Hold” by the six ratings firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 1 year […]

Thomson reuterVirtu financialZacks investment researchMagnus financial groupAprea therapeutics incSquarepoint opsVerition fund managementRoyal bankAprea therapeuticsGet ratingFinancial groupFund managementNasdaq apre